Matinas BioPharma (MTNB) Reports In-Line Q4 EPS

Matinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.03), in-line with the analyst estimate of ($0.03).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM